...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of clinical oncology >Intraoperative allogeneic blood transfusion is associated with adverse oncological outcomes in patients with surgically treated non-metastatic clear cell renal cell carcinoma
【24h】

Intraoperative allogeneic blood transfusion is associated with adverse oncological outcomes in patients with surgically treated non-metastatic clear cell renal cell carcinoma

机译：术中同种异体输血与手术治疗的非转移性透明细胞肾细胞癌患者的不良肿瘤性结果有关

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background The objective of this study was to provide more definitive information about the prognostic impact of perioperative blood transfusion (PBT) on patients with surgically treated renal cell carcinoma (RCC). Methods A database of 4019 patients with clear cell RCC, all of whom underwent radical or partial nephrectomy as primary therapy as part of a multi-institutional Korean collaboration between 1988 and 2015, was analyzed retrospectively. PBT was defined as transfusion of allogeneic red blood cells during surgery or postsurgical period. Receipt of a PBT, as well as the amount and time of blood transfusion (BT), was compared. Results Overall, 335 (8.3%) patients received a PBT: 84 received postoperative BT, 202 received intraoperative BT, and 49 received both intraoperative and postoperative BT. Patients receiving a PBT had a poor preoperative immuno-nutritional status, and aggressive tumor characteristics. Multivariate analyses identified PBT as an independent predictor of recurrence-free survival and cancer-specific survival. Prognostic impact of PBT was restricted to those with locally advanced stage (pT3-4), and who underwent radical nephrectomy. Among patients who received a PBT, intraoperative (but not postoperative) BT was a prognostic factor for survival. Among patients who received intraoperative BT, those receiving three or more transfusion units had a significantly worse survival. Conclusion Receipt of a PBT was an independent predictor of RFS and CSS in patients with surgically treated RCC, specifically locally advanced disease. Regarding the prognostic impact of timing or dose of PBT on survival, intraoperative BT and >= 3 pRBC units were associated with adverse oncological outcomes.
机译：背景技术本研究的目的是提供关于围手术期输血（PBT）对手术治疗肾细胞癌（RCC）患者的预后影响的更新信息。方法回顾性地分析了4019例含有透明细胞RCC患者的4019例患者患者，所有这些患者作为1988年至2015年之间的多机构韩国合作的一部分，所有受自由基或部分肾切除术为主要疗法。 PBT被定义为手术期间同种异体红细胞的输血或后期。比较了PBT，以及输血量和时间（BT）。结果总体而言，335名（8.3％）患者接受PBT：84术后BT，202次接受术中BT，49个术中和术后BT。接受PBT的患者术前免疫营养状况差，致癌肿瘤特征差。多变量分析确定了PBT作为无复发存活和癌症的存活率的独立预测因子。 PBT的预后撞击仅限于局部晚期阶段（PT3-4）的影响，以及接受自由基肾切除术的人。在接受PBT的患者中，术中（但不是术后）BT是存活的预后因素。在接受术中BT的患者中，接受三种或更多个输血单元的人的存活率显着更差。结论PBT的收据是手术治疗RCC患者的RFS和CSS的独立预测因子，特异性局部晚期疾病。关于时序或剂量PBT对存活的预后影响，术中BT和> = 3个PRBC单元与不良肿瘤性结果有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号